Nav: Home

Alirocumab in hypercholesterolaemia or mixed dyslipidaemia: Added benefit not proven

February 17, 2016

The drug alirocumab (trade name: Praluent) has been approved since September 2015 for adults with hypercholesterolaemia or mixed dyslipidaemia whose cholesterol levels are not adequately lowered by diet and other drugs. It can also be used if statins are not a treatment option or are not tolerated because of adverse events.

The German Institute for Quality and Efficiency in Health Care (IQWiG) recently examined the added benefit of a similar drug pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG): evolocumab. The Federal Joint Committee (G-BA) now commissioned the Institute to also assess the drug manufacturer dossier on alirocumab. An added benefit in comparison with the appropriate comparator therapies is also not proven for this drug.

Monoclonal antibodies aim to lower LDL levels

Hypercholesterolaemia is diagnosed when the LDL cholesterol levels in the blood are high. In mixed dyslipidaemia, triglyceride levels may also be elevated. Untreated, both disorders can lead to cardiovascular disease such as coronary heart disease or arteriosclerosis if the values are very high.

Standard treatment options include diet in combination with lipid-lowering drugs (such as statins) or, if drugs and diet are insufficient, LDL apheresis, a procedure similar to dialysis, in combination with drug treatment. In LDL apheresis, LDL cholesterol is eliminated from the blood. For some patients however, these measures are insufficient.

Drugs known as PCSK9 inhibitors, such as alirocumab or evolocumab, help remove LDL cholesterol in the liver. The enzyme PCSK9 binds to LDL receptors of the liver cells instead of LDL cholesterol, causing the receptors to be broken down, thus increasing the cholesterol level in the blood. If a substance such as alirocumab blocks this enzyme, the number of LDL receptors is increased and cholesterol levels can drop.

G-BA defined three research questions

The G-BA specified different appropriate comparator therapies for three patient populations: In patients who tolerate statins, but do not achieve their target cholesterol levels even on the their maximum tolerated statin dose, alirocumab in combination with a statin and, if applicable, further lipid-lowering drugs was to be compared with a maximum tolerated drug and dietary treatment for lowering lipid levels.

In patients for whom statin treatment is not an option alirocumab was to be compared with a different lipid-lowering drug as monotherapy. And for patients for whom drug and dietary options for lowering lipid levels are exhausted LDL apheresis was to be the appropriate comparator therapy.

Wrong population, wrong comparator therapies, studies too short

None of the twelve studies in total cited by the manufacturer in its dossier for these three research questions answers the relevant research questions of the early benefit assessment. Firstly, part of the patients had received no prior therapy with their maximum tolerated dose of statins in numerous studies on the first research question. This is a prerequisite for treatment with alirocumab, however.

Secondly, the appropriate comparator therapy was not adhered to in many studies, or no data were available for those study participants who corresponded to the inclusion criteria. And thirdly, some of the studies were too short, as was the case already with evolocumab. Hypercholesterolaemia and mixed dyslipidaemia are chronic diseases; alirocumab is intended for long-term treatment. Hence studies with a minimum duration of one year are required to assess benefit or harm.

Since none of the studies was relevant for the benefit assessment, there was no hint of an added benefit of alirocumab in comparison with the respective appropriate comparator therapy for any of the therapeutic indications.

G-BA decides on the extent of added benefit

This dossier assessment is part of the early benefit assessment according to AMNOG supervised by the G-BA. After publication of the dossier assessment, the G-BA conducts a commenting procedure and makes a final decision on the extent of the added benefit.

An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the website », published by IQWiG, provides easily understandable German-language information.

More English-language information will be available soon (Sections 2.1 to 2.6 of the dossier assessment as well as subsequently published health information on » If you would like to be informed when these documents are available, please send an e-mail to »

Institute for Quality and Efficiency in Health Care

Related Statins Articles:

Statins may not be used for protection against Parkinson's disease
Use of statins may speed up the onset of Parkinson's disease symptoms in people who are susceptible to the disease, according to Penn State College of Medicine researchers.
Statins associated with improved heart structure and function
Statins are associated with improved heart structure and function, according to research presented today at EuroCMR 2017.
Dietary supplement may carry both benefits and risks associated with statins
Red yeast rice (RYR) is contained in dietary supplements that are often used by patients with high cholesterol, and it is often proposed as an alternative therapy in those who experience side effects from statins.
Are cholesterol-lowering statins associated with reduced Alzheimer risk?
An analysis of Medicare data suggests that high use of cholesterol-lowering statins was associated with a reduced risk for Alzheimer disease but that reduction in risk varied by type of statin and race/ethnicity, findings that must be confirmed in clinical trials, according to a new article published online by JAMA Neurology.
Use of statins before cardiac arrest may aid survival afterwards
Patients who have been using cholesterol-lowering drugs known as statins fare better after a cardiac arrest than non-users.
Statins may be associated with reduced mortality in 4 common cancers
A diagnosis of high cholesterol is associated with reduced mortality and improved survival in the four most common cancers, according to research presented today at Frontiers in CardioVascular Biology 2016.
Did controversy over statins influence their use in the UK?
A period of controversy over the risks and benefits of statins, covered widely in the UK media, was followed by a temporary increase in the number of people stopping their statin treatment, finds a study in The BMJ today.
Why are women less likely to be prescribed statins than men?
Statins are equally effective at decreasing risk of coronary events in men and women, and yet women are less likely to be prescribed these cholesterol-lowering drugs than men.
Statins and colorectal cancer
A large case-control study published in this week's PLOS Medicine conducted by Ronac Mamtani, M.D., MSCE, an assistant professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA, and colleagues provides evidence that indication bias may explain the link between statin use and reduced colorectal cancer risk.
Statins cut tuberculosis treatment time in mice
In a study using mice, the Johns Hopkins University School of Medicine infectious disease experts have added to evidence that statin drugs -- known primarily for their cholesterol-lowering effects -- can significantly reduce the time it takes to clear tuberculosis infection.

Related Statins Reading:

The Truth About Statins: Risks and Alternatives to Cholesterol-Lowering Drugs
by Barbara H. Roberts M.D. (Author)

The Statin Damage Crisis
by Duane Graveline MD (Author)

Statin Nation: The Ill-Founded War on Cholesterol, What Really Causes Heart Disease, and the Truth About the Most Overprescribed Drugs in the World
by Justin Smith (Author)

The Dark Side of Statins: Plus: The Wonder of Cholesterol
by Duane Graveline MD (Author)

How Statin Drugs Really Lower Cholesterol: And Kill You One Cell at a Time
by James B. and Hannah Yoseph (Author)

Fat and Cholesterol Don't Cause Heart Attacks and Statins are Not The Solution
by Paul J. Rosch MD (Author), Zoë Harcombe PhD (Author), Malcolm Kendrick MD (Author), Uffe Ravnskov MD PhD (Author), Fred A. Kummerow PhD (Author), Harumi Okuyama PhD (Author), Peter H. Langsjoen MD (Author), Alena M. Langsjoen MS (Author), Naoki Ohara PhD (Author), David M. Diamond PhD (Author), Tomohito Hamazaki MD PhD (Author), Stephanie Seneff PhD (Author), Carlos Monteiro (Author), Kilmer S. McCully MD (Author), Luca Mascitelli MD (Author), Mark R. Goldstein MD (Author), Michel de Lorgeril MD (Author), Mikael Rabaeus MD (Author), Duane Graveline MD MPH (Author), Sherif Sultan MD Phd (Author), Edel P. Kavanagh PhD (Author)

The Great Cholesterol Myth: Why Lowering Your Cholesterol Won't Prevent Heart Disease-and the Statin-Free Plan That Will
by Jonny Bowden (Author), Stephen Sinatra (Author)

Natural Alternatives to Lipitor, Zocor & Other Statin Drugs (The Square One Health Guides)
by Jay S. Cohen (Author)

The Great Cholesterol Myth Now Includes 100 Recipes for Preventing and Reversing Heart Disease: Why Lowering Your Cholesterol Won't Prevent Heart Disease-and the Statin-Free Plan that Will
by Jonny Bowden (Author), Stephen Sinatra (Author), Deirdre Rawlings (Author)

A Statin Nation: Damaging Millions in a Brave New Post-health World
by Dr Malcolm Kendrick (Author)

Best Science Podcasts 2018

We have hand picked the best science podcasts for 2018. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Why We Hate
From bullying to hate crimes, cruelty is all around us. So what makes us hate? And is it learned or innate? This hour, TED speakers explore the causes and consequences of hate — and how we can fight it. Guests include reformed white nationalist Christian Picciolini, CNN commentator Sally Kohn, podcast host Dylan Marron, and writer Anand Giridharadas.
Now Playing: Science for the People

#482 Body Builders
This week we explore how science and technology can help us walk when we've lost our legs, see when we've gone blind, explore unfriendly environments, and maybe even make our bodies better, stronger, and faster than ever before. We speak to Adam Piore, author of the book "The Body Builders: Inside the Science of the Engineered Human", about the increasingly amazing ways bioengineering is being used to reverse engineer, rebuild, and augment human beings. And we speak with Ken Thomas, spacesuit engineer and author of the book "The Journey to Moonwalking: The People That Enabled Footprints on the Moon" about...